Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 1890
- Registration Number
- NCT02638103
- Locations
- 🇵🇱
Teva Investigational Site 53366, Lublin, Poland
🇵🇱Teva Investigational Site 53365, Poznan, Poland
🇯🇵Teva Investigational Site 84061, Sendai-shi, Japan
Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine
- First Posted Date
- 2015-12-14
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 875
- Registration Number
- NCT02629861
- Locations
- 🇺🇸
Teva Investigational Site 13536, Springfield, Missouri, United States
🇺🇸Teva Investigational Site 13609, Akron, Ohio, United States
🇺🇸Teva Investigational Site 13634, Akron, Ohio, United States
Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine
- First Posted Date
- 2015-12-04
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 1130
- Registration Number
- NCT02621931
- Locations
- 🇺🇸
Teva Investigational Site 13585, Chicago, Illinois, United States
🇺🇸Teva Investigational Site 13626, Columbus, Ohio, United States
🇺🇸Teva Investigational Site 13568, Encino, California, United States
Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma
- Conditions
- Persistent Asthma
- Interventions
- Drug: albuterol/salbutamolDrug: Beclomethasone dipropionate via 320 mcg BAIDrug: Beclomethasone Dipropionate 640Drug: PlaceboDrug: Beclomethasone dipropionate via 320 mcg MDI
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 713
- Registration Number
- NCT02513160
- Locations
- 🇺🇸
Teva Investigational Site 13391, Pittsburgh, Pennsylvania, United States
🇺🇸Teva Investigational Site 13420, San Diego, California, United States
🇺🇸Teva Investigational Site 13416, Miami, Florida, United States
An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils
- Conditions
- Elevated Blood EosinophilsOral Corticosteroid DependenceAsthma
- Interventions
- Drug: PlaceboDrug: Non-Oral Corticosteroid (non-OCS) Asthma MedicationDrug: Oral Corticosteroid (OCS)
- First Posted Date
- 2015-07-17
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 177
- Registration Number
- NCT02501629
- Locations
- 🇺🇸
Teva Investigational Site 13349, Cincinnati, Ohio, United States
🇺🇸Teva Investigational Site 13357, Bakersfield, California, United States
🇺🇸Teva Investigational Site 13365, Long Beach, California, United States
Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 861
- Registration Number
- NCT02499900
- Locations
- 🇺🇸
Teva Investigational Site 13483, Golden Valley, Minnesota, United States
🇧🇪Teva Investigational Site 37063, Edegem, Belgium
🇦🇷Teva Investigational Site 20062, Buenos Aires, Argentina
Study to Evaluate the Analgesic Efficacy and Safety of Hydrocodone Bitartrate/Acetaminophen Immediate-Release Tablets in Participants With Moderate to Severe Pain Following Bunionectomy
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 569
- Registration Number
- NCT02487108
- Locations
- 🇺🇸
Teva Investigational Site 13173, Anaheim, California, United States
🇺🇸Teva Investigational Site 13510, Phoenix, Arizona, United States
🇺🇸Teva Investigational Site 13174, Bakersfield, California, United States
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 468
- Registration Number
- NCT02452190
- Locations
- 🇺🇸
Teva Investigational Site 13215, Bakersfield, California, United States
🇺🇸Teva Investigational Site 13235, Shiloh, Illinois, United States
🇺🇸Teva Investigational Site 13208, Tallahassee, Florida, United States
Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older
- Conditions
- Asthma
- Interventions
- Drug: Treatment C Flovent
- First Posted Date
- 2015-05-07
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT02437604
- Locations
- 🇺🇸
Teva Investigational Site 13178, Raleigh, North Carolina, United States
🇺🇸Teva Investigational Site 13179, San Antonio, Texas, United States
🇺🇸Teva Investigational Site 13177, Edmond, Oklahoma, United States
Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)
- First Posted Date
- 2015-04-07
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT02410356
- Locations
- 🇺🇸
Teva Investigational Site 13166, Fountain Valley, California, United States
🇺🇸Teva Investigational Site 13142, Pittsburgh, Pennsylvania, United States
🇺🇸Teva Investigational Site 13144, Arlington, Texas, United States